Cargando…
Artificial intelligence in COVID-19 drug repurposing
Drug repurposing or repositioning is a technique whereby existing drugs are used to treat emerging and challenging diseases, including COVID-19. Drug repurposing has become a promising approach because of the opportunity for reduced development timelines and overall costs. In the big data era, artif...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500917/ https://www.ncbi.nlm.nih.gov/pubmed/32984792 http://dx.doi.org/10.1016/S2589-7500(20)30192-8 |
_version_ | 1783583949206847488 |
---|---|
author | Zhou, Yadi Wang, Fei Tang, Jian Nussinov, Ruth Cheng, Feixiong |
author_facet | Zhou, Yadi Wang, Fei Tang, Jian Nussinov, Ruth Cheng, Feixiong |
author_sort | Zhou, Yadi |
collection | PubMed |
description | Drug repurposing or repositioning is a technique whereby existing drugs are used to treat emerging and challenging diseases, including COVID-19. Drug repurposing has become a promising approach because of the opportunity for reduced development timelines and overall costs. In the big data era, artificial intelligence (AI) and network medicine offer cutting-edge application of information science to defining disease, medicine, therapeutics, and identifying targets with the least error. In this Review, we introduce guidelines on how to use AI for accelerating drug repurposing or repositioning, for which AI approaches are not just formidable but are also necessary. We discuss how to use AI models in precision medicine, and as an example, how AI models can accelerate COVID-19 drug repurposing. Rapidly developing, powerful, and innovative AI and network medicine technologies can expedite therapeutic development. This Review provides a strong rationale for using AI-based assistive tools for drug repurposing medications for human disease, including during the COVID-19 pandemic. |
format | Online Article Text |
id | pubmed-7500917 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | The Author(s). Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-75009172020-09-21 Artificial intelligence in COVID-19 drug repurposing Zhou, Yadi Wang, Fei Tang, Jian Nussinov, Ruth Cheng, Feixiong Lancet Digit Health Review Drug repurposing or repositioning is a technique whereby existing drugs are used to treat emerging and challenging diseases, including COVID-19. Drug repurposing has become a promising approach because of the opportunity for reduced development timelines and overall costs. In the big data era, artificial intelligence (AI) and network medicine offer cutting-edge application of information science to defining disease, medicine, therapeutics, and identifying targets with the least error. In this Review, we introduce guidelines on how to use AI for accelerating drug repurposing or repositioning, for which AI approaches are not just formidable but are also necessary. We discuss how to use AI models in precision medicine, and as an example, how AI models can accelerate COVID-19 drug repurposing. Rapidly developing, powerful, and innovative AI and network medicine technologies can expedite therapeutic development. This Review provides a strong rationale for using AI-based assistive tools for drug repurposing medications for human disease, including during the COVID-19 pandemic. The Author(s). Published by Elsevier Ltd. 2020-12 2020-09-18 /pmc/articles/PMC7500917/ /pubmed/32984792 http://dx.doi.org/10.1016/S2589-7500(20)30192-8 Text en © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review Zhou, Yadi Wang, Fei Tang, Jian Nussinov, Ruth Cheng, Feixiong Artificial intelligence in COVID-19 drug repurposing |
title | Artificial intelligence in COVID-19 drug repurposing |
title_full | Artificial intelligence in COVID-19 drug repurposing |
title_fullStr | Artificial intelligence in COVID-19 drug repurposing |
title_full_unstemmed | Artificial intelligence in COVID-19 drug repurposing |
title_short | Artificial intelligence in COVID-19 drug repurposing |
title_sort | artificial intelligence in covid-19 drug repurposing |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500917/ https://www.ncbi.nlm.nih.gov/pubmed/32984792 http://dx.doi.org/10.1016/S2589-7500(20)30192-8 |
work_keys_str_mv | AT zhouyadi artificialintelligenceincovid19drugrepurposing AT wangfei artificialintelligenceincovid19drugrepurposing AT tangjian artificialintelligenceincovid19drugrepurposing AT nussinovruth artificialintelligenceincovid19drugrepurposing AT chengfeixiong artificialintelligenceincovid19drugrepurposing |